Collegium Pharmaceutical Stock News

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Cantel Medical

Collegium Pharmaceutical Inc (NASDAQ:COLL) – Investment analysts at G.Research lowered their FY2020 earnings estimates for Collegium Pharmaceutical in a research note issued on Tuesday, March 3rd. G

Mackay Shields LLC acquired a new position in Collegium Pharmaceutical Inc (NASDAQ:COLL) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fu

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on EyePoint Pharmaceuticals (EYPT) and Aurinia

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on EyePoint Pharmaceuticals ( EYPT – Research Report ) and Aurinia Pharmaceuticals ( AUPH – Research R

Bank of Montreal Can lifted its position in Collegium Pharmaceutical Inc (NASDAQ:COLL) by 248.7% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 252,22

Collegium Pharmaceutical Inc (NASDAQ:COLL) – Research analysts at G.Research upped their FY2023 earnings per share (EPS) estimates for Collegium Pharmaceutical in a note issued to investors on Tuesd

In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Arcturus Therapeutics (ARCT), with a price target of $18.00. The

In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Arcturus Therapeutics ( ARCT – Research Report ), with a price target of $18.00 . The company’s shares closed la

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Antares Pharma (ATRS) and Durect (DRRX) with bullish

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Antares Pharma ( ATRS – Research Report ) and Durect ( DRRX – Research Report ) with bullish sentim